- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease (CD) Moderate to severe ulcerative colitis (MSUC)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 657.5KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 133.0KB)
Vedolizumab – November 2025
Vedolizumab: Powder for injection 300 mg; Entyvio® - November 2025
Last updated
5 November 2025